Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$20.50
-0.32-1.54%
At close: -
$20.50
0.000.00%
After Hours: Jun 20, 4:00 PM EDT
Comments
Loading...
Celldex Therapeutics Analyst Ratings and Price Targets | NASDAQ:CLDX | Benzinga
Celldex Therapeutics Inc has a consensus price target of $57 based on the ratings of 13 analysts. The high is $90 issued by Guggenheim on February 27, 2024. The low is $31 issued by Goldman Sachs on May 9, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and UBS on June 16, 2025, June 13, 2025, and May 9, 2025, respectively. With an average price target of $46 between HC Wainwright & Co., HC Wainwright & Co., and UBS, there's an implied 124.39% upside for Celldex Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
UBS
Goldman Sachs
Morgan Stanley
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Celldex Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/16/2025 | Buy Now | 143.9% | HC Wainwright & Co. | Joseph Pantginis40% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 06/13/2025 | Buy Now | 143.9% | HC Wainwright & Co. | Joseph Pantginis40% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2025 | Buy Now | 85.37% | UBS | Trung Huynh42% | $44 → $38 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | 51.22% | Goldman Sachs | Richard Law46% | $36 → $31 | Maintains | Neutral | Get Alert |
| 05/09/2025 | Buy Now | 109.76% | Morgan Stanley | Judah Frommer65% | $46 → $43 | Maintains | Overweight | Get Alert |
| 05/09/2025 | Buy Now | 143.9% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $50 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 04/28/2025 | Buy Now | 212.2% | Canaccord Genuity | Edward Nash68% | → $64 | Initiates | → Buy | Get Alert |
| 03/20/2025 | Buy Now | 124.39% | Morgan Stanley | Judah Frommer65% | → $46 | Initiates | → Overweight | Get Alert |
| 03/03/2025 | Buy Now | 75.61% | Goldman Sachs | Richard Law46% | $42 → $36 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2025 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 114.63% | UBS | Trung Huynh42% | → $44 | Initiates | → Buy | Get Alert |
| 01/29/2025 | Buy Now | 226.83% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 01/02/2025 | Buy Now | 226.83% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 12/20/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 10/28/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 10/07/2024 | Buy Now | 241.46% | Citigroup | David Lebowitz55% | → $70 | Initiates | → Buy | Get Alert |
| 09/30/2024 | Buy Now | 119.51% | Goldman Sachs | Richard Law46% | → $45 | Initiates | → Neutral | Get Alert |
| 09/27/2024 | Buy Now | — | Wolfe Research | Andy Chen48% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 09/26/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2024 | Buy Now | 148.78% | Wolfe Research | Andy Chen48% | $51 → $51 | Reiterates | Outperform → Outperform | Get Alert |
| 09/20/2024 | Buy Now | 226.83% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 09/18/2024 | Buy Now | 226.83% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 226.83% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 226.83% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 08/12/2024 | Buy Now | 80.49% | Wells Fargo | Derek Archila62% | $35 → $37 | Maintains | Equal-Weight | Get Alert |
| 08/12/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 07/30/2024 | Buy Now | 226.83% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 07/30/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 07/16/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 06/18/2024 | Buy Now | 226.83% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen48% | — | Initiates | → Outperform | Get Alert |
| 06/03/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 226.83% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 02/27/2024 | Buy Now | 339.02% | Guggenheim | Yatin Suneja55% | $72 → $90 | Maintains | Buy | Get Alert |
| 12/20/2023 | Buy Now | — | TD Cowen | Yaron Werber36% | — | Initiates | → Outperform | Get Alert |
| 11/10/2023 | Buy Now | 31.71% | Wells Fargo | Derek Archila62% | → $27 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/06/2023 | Buy Now | 290.24% | HC Wainwright & Co. | Joseph Pantginis40% | $73 → $80 | Maintains | Buy | Get Alert |
| 11/03/2023 | Buy Now | 153.66% | Cantor Fitzgerald | Kristen Kluska71% | $54 → $52 | Maintains | Overweight | Get Alert |
| 10/12/2023 | Buy Now | 163.41% | Cantor Fitzgerald | Kristen Kluska71% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 09/27/2023 | Buy Now | 163.41% | Cantor Fitzgerald | Kristen Kluska71% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 2.44% | Wells Fargo | Derek Archila62% | → $21 | Initiates | → Underweight | Get Alert |
| 08/16/2023 | Buy Now | 163.41% | Cantor Fitzgerald | Kristen Kluska71% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/10/2023 | Buy Now | 256.1% | HC Wainwright & Co. | Joseph Pantginis40% | → $73 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 256.1% | HC Wainwright & Co. | Joseph Pantginis40% | → $73 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | Buy Now | 256.1% | HC Wainwright & Co. | Joseph Pantginis40% | → $73 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2023 | Buy Now | 256.1% | HC Wainwright & Co. | Joseph Pantginis40% | → $73 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | 163.41% | Cantor Fitzgerald | Kristen Kluska71% | $55 → $54 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | 256.1% | HC Wainwright & Co. | Joseph Pantginis40% | → $73 | Reiterates | → Buy | Get Alert |
| 03/22/2023 | Buy Now | 256.1% | HC Wainwright & Co. | Joseph Pantginis40% | → $73 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 256.1% | HC Wainwright & Co. | Joseph Pantginis40% | → $73 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 256.1% | HC Wainwright & Co. | Joseph Pantginis40% | → $73 | Reiterates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | 207.32% | Guggenheim | Yatin Suneja55% | $68 → $63 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 212.2% | SVB Leerink | Thomas Smith33% | $68 → $64 | Maintains | Outperform | Get Alert |
| 07/01/2022 | Buy Now | 256.1% | HC Wainwright & Co. | Joseph Hafling29% | $60 → $73 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Celldex Therapeutics (CLDX) stock?
The latest price target for Celldex Therapeutics (NASDAQ:CLDX) was reported by HC Wainwright & Co. on June 16, 2025. The analyst firm set a price target for $50.00 expecting CLDX to rise to within 12 months (a possible 143.90% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Celldex Therapeutics (CLDX)?
The latest analyst rating for Celldex Therapeutics (NASDAQ:CLDX) was provided by HC Wainwright & Co., and Celldex Therapeutics reiterated their buy rating.
When was the last upgrade for Celldex Therapeutics (CLDX)?
The last upgrade for Celldex Therapeutics Inc happened on November 10, 2023 when Wells Fargo raised their price target to $27. Wells Fargo previously had an underweight for Celldex Therapeutics Inc.
When was the last downgrade for Celldex Therapeutics (CLDX)?
The last downgrade for Celldex Therapeutics Inc happened on September 27, 2024 when Wolfe Research changed their price target from N/A to N/A for Celldex Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Celldex Therapeutics (CLDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on June 16, 2025 so you should expect the next rating to be made available sometime around June 16, 2026.
Is the Analyst Rating Celldex Therapeutics (CLDX) correct?
While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a reiterated with a price target of $50.00 to $50.00. The current price Celldex Therapeutics (CLDX) is trading at is $20.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
